Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services entities : Tscan therapeutics inc save search
TScan Therapeutics Announces Closing of Upsized Public Offering
Published: 2024-04-19 (Crawled : 14:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 1.04%
H: 4.55%
C: 0.0%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.35%
H: 1.39%
C: 0.33%
offering therapeutics
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
Published: 2024-04-17 (Crawled : 05:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -2.15%
H: 1.24%
C: -7.15%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.14%
H: 0.0%
C: 0.0%
million offering therapeutics
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -2.15%
H: 1.24%
C: -7.15%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -0.14%
H: 0.0%
C: 0.0%
million offering therapeutics
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -2.15%
H: 1.24%
C: -7.15%
update pipeline therapeutics
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 3.14%
H: 1.8%
C: 1.66%
medical therapeutics
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -1.3%
H: 0.0%
C: -9.89%
conference presentation therapeutics
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -3.27%
H: 8.09%
C: 5.15%
business year update therapeutics financial results
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -0.62%
H: 8.74%
C: 4.68%
conference health care therapeutics
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 1.33%
H: 2.92%
C: -0.88%
tsc-100 tsc-101 cibmtr therapeutics astct results
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 2.27%
H: 0.47%
C: -1.02%
cibmtr therapeutics astct results study
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
Published: 2024-02-06 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 1.08%
H: 7.31%
C: 5.53%
ALRN | $4.785 -4.3% -4.49% 85K
|
Health Technology
|
| O: -0.3%
H: 2.58%
C: -7.08%
therapeutics
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
ZVRA | $4.515 0.33% 0.33% 360K
|
n/a
|
| O: 0.42%
H: 3.33%
C: 2.83%
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -1.2%
H: 7.46%
C: 5.65%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 0.62%
H: 11.66%
C: 9.82%
therapeutics financial
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
Published: 2024-01-18 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 1.03%
H: 0.0%
C: -10.54%
award cibmtr presentation therapeutics astct
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
Published: 2024-01-04 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 1.59%
H: 7.29%
C: 0.52%
therapeutics
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
tsc-100 tsc-101 meeting therapeutics results
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 3.26%
H: 0.0%
C: -3.74%
global commercialization therapeutics
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -3.1%
H: 16.36%
C: 14.0%
tsc-100 tsc-101 ongoing meeting trial therapeutics results
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
Published: 2023-12-04 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 0.31%
H: 0.0%
C: -5.85%
technology therapeutics
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-09 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -4.37%
H: 10.34%
C: 3.61%
update therapeutics financial results
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: -2.7%
H: 15.11%
C: 14.11%
cancer tumor immunotherapy meeting program trial therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.